

REMARKS

Prior to this Preliminary Amendment, Claims 1-14 as presented in the annex to the International Preliminary Examination Report were pending. With this Preliminary Amendment, Claims 1-2 drafted in the European Swiss-type use format have been deleted, and Claims 5 and 14 have been amended and new Claims 15-16 added to remove multiple dependency. Applicants respectfully request these changes be entered into the application.

Payment for the fees associated with these claims as amended has been directed on the Transmittal Letter to the United States Designated/Elected Office Concerning a Filing Under 35 U.S.C. §371 filed concurrently herewith.

Respectfully submitted,

By: Karen L. Knezek
Karen L. Knezek
Registration No. 39,253

KLK:FIS

20 March 2002

SIDLEY AUSTIN BROWN & WOOD LLP

717 N. Harwood, Suite 3400

Dallas, Texas 75201

(214) 981-3300

(214) 981-3400 (FAX)


APPENDIX

VERSION WITH MARKINGS TO SHOW CHANGES MADE

The following is a marked-up version of the changes to claims which are being made in the attached Preliminary Amendment. Added material is underlined, and deleted material is bracketed.

IN THE CLAIMS

[1. Use of the compound



where R is CH₃ or an alkyl to prepare a pharmaceutical composition useful for effecting a reduction in whole blood viscosity in a mammal.]

[2. The use of Claim 1, wherein said alkyl having 2 to 6 carbons.]

5. The method of Claim 3[or 4], wherein said effective amount is from about 1 milligram to about 6 milligrams per kilogram body weight.

14. The method of Claim 12[or 13], wherein said effective amount is from about 1 milligram to about 6 milligrams per kilogram body weight.

15. The method of Claim 4, wherein said effective amount is from about 1 milligram to about 6 milligrams per kilogram body weight.

16. The method of Claim 13, wherein said effective amount is from about 1 milligram to about 6 milligrams per kilogram body weight.